OrbiMed’s Mersana Therapeutics MRSN Stock Holding History

OrbiMed’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-288,597	Closed	-$23.7M	–	138
2023 Q2	$23.7M	Sell	288,597 -71,860	-20%	-$10.5M	0.43%	64
2023 Q1	$37M	Hold	360,457	–	–	0.73%	44
2022 Q4	$52.8M	Hold	360,457	–	–	1.01%	37
2022 Q3	$60.9K	Hold	360,457	–	–	1.13%	31
2022 Q2	$41.6K	Buy	360,457 +168,901	+88%	+$15.9M	0.76%	44
2022 Q1	$19.1M	Buy	191,556 +76,002	+66%	+$8.88M	0.31%	68
2021 Q4	$18M	Hold	115,554	–	–	0.23%	88
2021 Q3	$27.2M	Buy	115,554 +3,544	+3%	+$1.04M	0.3%	82
2021 Q2	$38M	Buy	112,010 +36,310	+48%	+$13.7M	0.39%	68
2021 Q1	$30.6M	Buy	75,700 +44,766	+145%	+$21.7M	0.29%	82
2020 Q4	$20.6M	Sell	30,934 -22,220	-42%	-$12.4M	0.18%	101
2020 Q3	$24.7M	Sell	53,154 -23,246	-30%	-$11.7M	0.31%	79
2020 Q2	$44.7M	Buy	76,400 +22,531	+42%	+$7.69M	0.63%	50
2020 Q1	$7.85M	Sell	53,869 -29,064	-35%	-$5.08M	0.13%	93
2019 Q4	$11.9M	Buy	82,933 +7,288	+10%	+$533K	0.17%	78
2019 Q3	$2.99M	Hold	75,645	–	–	0.06%	103
2019 Q2	$7.66M	Hold	75,645	–	–	0.12%	97
2019 Q1	$9.95M	Buy	+75,645	New	+$9.52M	0.16%	91

Other funds holding MRSN

EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return